Welsh drug body issues new recommendations

The All Wales Medicines Strategy Group (AWMSG) has accepted darunavir (Prezista), co-administered with low-dose ritonavir, for use within NHS Wales in treatment-naïve patients with HIV-1 infection.

The following two drugs were rejected by the AWMSG on the grounds of unproven cost-effectiveness:

  • Ranolazine (Ranexa) for stable angina pectoris.
  • Degarelix (Firmagon) for advanced hormone-dependent prostate cancer.

Firmagon was previously rejected by the Scottish Medicines Consortium (SMC) for the same indication.

Further information: AWMSG

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New guidance for minimising psychological impact of COVID-19 pandemic in primary care patients
Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

MIMS launches Respiratory and Allergy Learning webinars

MIMS launches Respiratory and Allergy Learning webinars

Join us for the 2020 Respiratory and Allergy Learning...